Sharpe ratio
0.67Return earned for the risk taken.
Moderate
Moderate risk-adjusted returns. The reward for risk has been average.
+16.82%1Y Absolute Return
-0.35%1D
Loading NAV history…
Past performance is not an indicator of future returns.
Returns calculator comparison
Compare an illustrative investment outcome across return assumptions.
| Asset | Projected corpus | Total invested | Gain | Annual return |
|---|---|---|---|---|
| ITI Pharma and Healthcare Fund - Direct Plan - Growth OptionFund 5Y annualised return | ₹10,77,453 | ₹7,32,612 | ₹3,44,841 | +15.46% |
| EPFIllustrative annual assumption | ₹8,95,132 | ₹7,32,612 | ₹1,62,520 | +8.25% |
| Residential propertyIllustrative annual assumption | ₹8,67,662 | ₹7,32,612 | ₹1,35,050 | +7.00% |
| PPFIllustrative annual assumption | ₹8,69,819 | ₹7,32,612 | ₹1,37,207 | +7.10% |
| Bank fixed depositIllustrative annual assumption | ₹8,56,981 | ₹7,32,612 | ₹1,24,369 | +6.50% |
| GoldIllustrative annual assumption | ₹8,67,662 | ₹7,32,612 | ₹1,35,050 | +7.00% |
| Savings accountIllustrative annual assumption | ₹7,86,827 | ₹7,32,612 | ₹54,215 | +3.00% |
Illustration only. Fund results use the available NAV-derived annualised return and can be negative. Reference rows are assumptions, not current quoted rates or guaranteed returns; property excludes transaction costs, taxes, and liquidity constraints. Mutual fund investments are subject to market risk.
Wealth multiple
₹1 became₹1.15
₹1 Lakh since launch₹1.15 Lakh
Fund age5.0 yrs
Fund information
Scheme code149268
ISININF00XX01BO9
BenchmarkNIFTY Healthcare TRI.
CategoryEquity Scheme - Sectoral/ Thematic
Expense ratio0.92%
Exit loadExit load of 0.50%, if redeemed within 3 months.
Minimum SIP₹500 SIP
Return comparison
118th / 932 in category| Period | Fund | Benchmark | Category avg |
|---|---|---|---|
| 1M | +198.02% | — | — |
| 3M | +15.83% | — | — |
| 6M | +26.30% | — | — |
| 1Y | +16.82% | — | +4.16% |
| 3Y | +20.55% | — | +12.54% |
| 5Y | +15.46% | — | +10.04% |
| Since Launch | +15.48% | — | — |
Risk-adjusted performance
Every measure is expanded with a plain-language reading of the latest calculated value.
Sortino ratio
0.97Return earned while limiting downside risk.
Moderate
Moderate downside risk-adjusted performance.
Standard deviation
13.96%How much the fund’s returns fluctuate over time.
Moderate volatility
Returns can move up and down noticeably.
Beta
—How closely the fund moves with the market.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Alpha
—Extra return generated above the benchmark.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Treynor ratio
—Return earned for each unit of market risk taken.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Calmar ratio
0.88How well the fund rewarded investors relative to its biggest decline.
Good
Good return relative to the drawdowns experienced.
Information ratio
—How consistently the fund outperformed its benchmark.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Portfolio allocation
Latest disclosed portfolio mix
Asset allocation
Allocation data has not been disclosed.
Market cap allocation
Sector allocation
Equity exposure by sector
Top holdings
10 of 39 disclosed positions
| Holding | Sector | Instrument type | Weight |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 13.26% |
| Divi's Laboratories Ltd | Healthcare | Equity | 7.97% |
| Apollo Hospitals Enterprise Ltd | Healthcare | Equity | 6.05% |
| Max Healthcare Institute Ltd | Healthcare | Equity | 5.05% |
| Torrent Pharmaceuticals Ltd | Healthcare | Equity | 4.84% |
| Cipla Ltd | Healthcare | Equity | 4.43% |
| Dr. Reddy's Laboratories Ltd | Healthcare | Equity | 4.41% |
| Laurus Labs Ltd | Healthcare | Equity | 4.21% |
| Aurobindo Pharma Ltd | Healthcare | Equity | 3.84% |
| Mankind Pharma Ltd. | Healthcare | Equity | 3.39% |
Fund management
AN
Animesh Singh
Since 2026 · Prior to joining the ITI AMC, he was associated with Julius Baer wealth Advisor, Centrum Wealth, Nippon Life India Asset Management Ltd, Reliance Portfolio Management Services, KSBL and SSKI Securities.
Post Graduate Diploma in Management, Bachelor of Honours -(Economics) CFA - USA Certification.
NI
Nilay Dalal
Since 2026 · Prior to joining ITI Mutual Fund, he has with Axis Asset Management Company, SBI Life Insurance Company Ltd & MAQ Software Pvt Ltd.
Mr. Nilay holds a degree in B.E (Computer) from D.J Sanghvi College of Engg & master’s in management studies in KJ Somaiya Institute of Management Studies & Research.
Compare similar funds
No comparable category funds are available yet.
Summary
A very high-risk equity scheme - sectoral/ thematic fund. Ahead of its category average over 3Y by 8.0 points. Healthcare makes up 94% — trouble in that sector hits the whole fund.
Strengths
- Ahead of its category average over 3Y by 8.0 points.
- Losses and swings stayed contained — worst fall -17.7%, volatility 14.0%.
- Ranks 118 of 932 in its category over 1 year.
Weaknesses
- None
Ideal investor
- Needs a 5–7+ years horizon to ride out its very high risk level.
- Good fit for SIPs — spreading purchases smooths out 14.0% volatility.
Risk drivers
- Healthcare makes up 94% — trouble in that sector hits the whole fund.